(0 items)
Small Medium Large | Print-Friendly Version of this Page  | Email this Page to a Friend
Skip Navigation Links
Press Releases
Hot Topics
Statements
Comments
Correspondence
White Papers
Contact Public Relations
AABB > Press Room > Correspondence

Letter to the FDA Nominating Industry Representatives to BPAC – 2/28/08 

28 February 2008

Mr. Donald W. Jehn

Division of Scientific Advisors and Consultants,

Center for Biologics Evaluation and Research,

Food and Drug Administration (HFM-71)

1401 Rockville Pike, Rockville, MD  20892

Dear Mr. Jehn,

 

AABB, American Red Cross, America’s Blood Centers, and Plasma Protein Therapeutics Association wish to nominate Celso Bianco, MD, (primary representative) and Donald Baker, PhD, (alternate representative) to serve on the Blood Products Advisory Committee (BPAC) as an industry representative.

 

As you know we believe that the issues faced by the blood industry and the plasma industry are too diverse to be adequately represented by one individual on the BPAC. We ask that both representatives be seated for BPAC meetings so that for any particular issue the primary and alternate can decide between themselves who has the best expertise to respond. 

 

A copy of the curriculum vitae for each nominee is attached.

 

If you have questions, please contact me at (919) 658-1689, or by email at acarrgreer@aabb.org.  Thank you for your consideration on this important issue.

 

Sincerely,

 

 

M. Allene Carr-Greer

Director, Regulatory Affairs

 

CC:         Chris Hrouda

                EVP, Biomedical Services

                American Red Cross

 

                Jim MacPherson

                CEO

                America’s Blood Centers

 

                Mary Gustafson,

                VP, Global Regulatory Policy

                Plasma Protein Therapeutics Association

Home  |  Site Map  | AABB © 2014. All rights reserved. |  Privacy Statement  |  Terms of Use